{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:57:17Z","timestamp":1760954237984},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"E.U. \u2014 European Social Fund","award":["PENED 2003, code 03\u0395\u0394970"],"award-info":[{"award-number":["PENED 2003, code 03\u0395\u0394970"]}]},{"name":"Greek Ministry of Development-GSRT"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.bbagen.2013.01.020","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T18:15:15Z","timestamp":1360088115000},"page":"3625-3634","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease"],"prefix":"10.1016","volume":"1830","author":[{"given":"P.G.","family":"Dedes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kanakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch.","family":"Gialeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Theocharis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Tsegenidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kletsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.N.","family":"Tzanakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.K.","family":"Karamanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2013.01.020_bb0005","series-title":"Principles and Practice of Oncology","first-page":"2713","article-title":"Metastatic cancer to the bone","author":"Brown","year":"2001"},{"issue":"19","key":"10.1016\/j.bbagen.2013.01.020_bb0010","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1111\/j.1742-4658.2010.07796.x","article-title":"Proteoglycans in health and disease: emerging concepts and future directions","volume":"277","author":"Iozzo","year":"2010","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.bbagen.2013.01.020_bb0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","article-title":"The microenvironment of the tumour\u2013host interface","volume":"411","author":"Liotta","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0025","first-page":"2651","article-title":"Tumor heterogeneity and the biology of cancer invasion and metastasis","volume":"38","author":"Fidler","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199003013220907","article-title":"The cellular basis of site-specific tumor metastasis","volume":"322","author":"Zetter","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"FEBS J."},{"issue":"15","key":"10.1016\/j.bbagen.2013.01.020_bb0040","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2002.20.15.3191","article-title":"Bisphosphonates and tumor burden","volume":"20","author":"Mundy","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0045","first-page":"584","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2174\/092986711795471275","article-title":"Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions","volume":"18","author":"Labropoulou","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0055","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology","volume":"16","author":"Body","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00223-002-2017-2","article-title":"The role of prenylated small GTP-binding proteins in the regulation of osteoclast function","volume":"72","author":"Coxon","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminoncol.2010.10.005","article-title":"Antitumor effects and anticancer applications of bisphosphonates","volume":"37","author":"Morgan","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0075","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0080","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0085","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","article-title":"Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid","volume":"1820","author":"Dedes","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0090","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0095","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bbagen.2013.01.020_bb0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0105","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.bbagen.2013.01.020_bb0110","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrclinonc.2010.134","article-title":"Future directions of bone-targeted therapy for metastatic breast cancer","volume":"7","author":"Onishi","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbagen.2013.01.020_bb0115","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1515\/bc.2010.149","article-title":"Physiology and pathophysiology of the RANKL\/RANK system","volume":"391","author":"Hanada","year":"2010","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02411252","article-title":"Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function","volume":"34","author":"Minkin","year":"1982","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00223-001-2122-7","article-title":"Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density","volume":"71","author":"Halleen","year":"2002","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bone.2010.09.016","article-title":"Integrins and bone metastasis: integrating tumor cell and stromal cell interactions","volume":"48","author":"Schneider","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bbagen.2013.01.020_bb0135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1083\/jcb.200212082","article-title":"Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin","volume":"162","author":"Faccio","year":"2003","journal-title":"J. Cell Biol."},{"issue":"48","key":"10.1016\/j.bbagen.2013.01.020_bb0140","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","article-title":"The collagenolytic activity of cathepsin K is unique among mammalian proteinases","volume":"273","author":"Garnero","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"6484","key":"10.1016\/j.bbagen.2013.01.020_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/370061a0","article-title":"A matrix metalloproteinase expressed on the surface of invasive tumour cells","volume":"370","author":"Sato","year":"1994","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbagen.2013.01.020_bb0150","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1083\/jcb.151.4.879","article-title":"Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones","volume":"151","author":"Engsig","year":"2000","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbagen.2013.01.020_bb0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"69","key":"10.1016\/j.bbagen.2013.01.020_bb0160","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-08-3949","article-title":"Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis","volume":"2","author":"Thiolloy","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0165","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","article-title":"Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells","volume":"100","author":"Mancino","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ijc.20056","article-title":"Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte\/macrophage colony-stimulating factor","volume":"109","author":"Morgan","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbagen.2013.01.020_bb0180","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2008.03.026","article-title":"Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation","volume":"43","author":"Guo","year":"2008","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10549-006-9438-y","article-title":"RANKL-dependent and RANKL-independent mechanisms of macrophage\u2013osteoclast differentiation in breast cancer","volume":"105","author":"Lau","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.bbagen.2013.01.020_bb0190","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0195","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein\u2013dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.bbagen.2013.01.020_bb0200","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1210\/endo.139.3.5818","article-title":"Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption","volume":"139","author":"Kusano","year":"1998","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.bbagen.2013.01.020_bb0205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00210-010-0596-4","article-title":"Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis","volume":"383","author":"Kimachi","year":"2011","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbagen.2013.01.020_bb0210","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1742-7843.2005.pto_176.x","article-title":"In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts","volume":"97","author":"Kellinsalmi","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.bbagen.2013.01.020_bb0215","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0009-9120(97)00113-6","article-title":"Biochemical markers of bone metabolism: an overview","volume":"30","author":"Christenson","year":"1997","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bbagen.2013.01.020_bb0220","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 3","key":"10.1016\/j.bbagen.2013.01.020_bb0225","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cncr.11132","article-title":"Mechanisms of osteolytic bone metastases in breast carcinoma","volume":"97","author":"K\u00e4k\u00f6nen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0230","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbagen.2013.01.020_bb0235","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/S0149-2918(03)80327-2","article-title":"Zoledronic acid: a new parenteral bisphosphonate","volume":"25","author":"Edward","year":"2003","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bbagen.2013.01.020_bb0245","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","article-title":"Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line","volume":"84","author":"Mackie","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(95)00426-2","article-title":"Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures","volume":"18","author":"Nishikawa","year":"1996","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S8756-3282(01)00655-X","volume":"30","author":"Van Beek","year":"2002","journal-title":"Bone"},{"issue":"23","key":"10.1016\/j.bbagen.2013.01.020_bb0260","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","article-title":"Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway","volume":"65","author":"Bendre","year":"2005","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bbagen.2013.01.020_bb0265","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI119435","article-title":"Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2","volume":"99","author":"Yoneda","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbagen.2013.01.020_bb0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0167-4889(93)90159-M","article-title":"Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2","volume":"1177","author":"Hill","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.bbagen.2013.01.020_bb0275","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.bjc.6600858","article-title":"Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis","volume":"88","author":"Ohshiba","year":"2003","journal-title":"Br. J. Cancer"}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416513000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416513000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T08:12:12Z","timestamp":1562659932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416513000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0304416513000330"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2013.01.020","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2013.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}